Key facts
- This page summarizes Brian C. Stephenson's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2025, 17:36.
Brian C. Stephenson - 25 Feb 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Reporting relationship
- CFO and Treasurer
- Issuer ticker
- BBIO
- Reported as of
- 25 Feb 2025
- Net transaction value
- -$137,615
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2025, 17:36:47 UTC
- Prior SEC filing
- 19 Feb 2025
- Next SEC filing
- 23 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian C. Stephenson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian C. Stephenson filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 27 Feb 2025.
Change
- Previous filing in this sequence was filed on 19 Feb 2025.
- Current net transaction value: -$137,615.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- $144,500
- Shares
- +8,500
- Change %
- +8.3%
- Price
- $17.00
- Shares after
- 110,964
- Date
- 25 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Sale
- Transaction value
- $278,697
- Shares
- -8,400
- Change %
- -7.6%
- Price
- $33.18
- Shares after
- 102,564
- Date
- 25 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
BBIO
transaction
Common Stock
Sale
- Transaction value
- $3,418
- Shares
- -100
- Change %
- -0.1%
- Price
- $34.18
- Shares after
- 102,464
- Date
- 25 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBIO
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -8,500
- Change %
- -1.9%
- Price
- $0.000000
- Shares after
- 440,170
- Date
- 25 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,500
- Exercise price
- $17.00
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
Footnote F2
Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Footnote F3
The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.